Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy.
Harmen ReyngoudtFiona E SmithEricky Caldas de Almeida AraújoIan WilsonRoberto Fernández-TorrónMeredith K JamesUrsula R MooreJordi Díaz-ManeraBenjamin MartyNoura AzzabouHeather GordishLaura RufibachTim HodgsonDorothy WallaceLouise WardJean-Marc BoisserieJulien Le LouërHeather HilsdenHelen SutherlandAurélie CanalJean-Yves HogrelMarni JacobsTanya StojkovicKate BushbyAnna Mayhewnull nullVolker StraubPierre G CarlierAndrew M BlamirePublished in: Journal of cachexia, sarcopenia and muscle (2022)
P MRS measurements in a heterogeneous group of dysferlinopathy patients can measure significant changes over the course of 3 years. These data can be used as reference values in view of future clinical trials in dysferlinopathy or comparisons with quantitative MRI/S data obtained in other limb-girdle muscular dystrophy subtypes.
Keyphrases
- muscular dystrophy
- magnetic resonance imaging
- lower limb
- clinical trial
- end stage renal disease
- electronic health record
- contrast enhanced
- ejection fraction
- newly diagnosed
- high resolution
- chronic kidney disease
- big data
- skeletal muscle
- randomized controlled trial
- current status
- diffusion weighted imaging
- patient reported outcomes
- magnetic resonance
- artificial intelligence
- patient reported
- open label
- double blind